Breaking News Instant updates and real-time market news.

BAC

Bank of America

$32.42

0.39 (1.22%)

, MU

Micron

$47.98

1.45 (3.12%)

07:35
02/27/18
02/27
07:35
02/27/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Bank of America (BAC), Micron (MU), Exxon Mobil (XOM), Celgene (CELG), Macy's (M), Transocean (RIG), Mondelez (MDLZ), Colgate Palmolive (CL), Wayfair (W), and Endo (ENDP).

BAC

Bank of America

$32.42

0.39 (1.22%)

MU

Micron

$47.98

1.45 (3.12%)

XOM

Exxon Mobil

$78.84

1.31 (1.69%)

CELG

Celgene

$96.49

0.88 (0.92%)

M

Macy's

$27.45

0.71 (2.66%)

RIG

Transocean

$9.67

-0.03 (-0.31%)

MDLZ

Mondelez

$44.77

1.02 (2.33%)

CL

Colgate-Palmolive

$71.07

0.77 (1.10%)

W

Wayfair

$75.01

-0.24 (-0.32%)

ENDP

Endo

$6.84

-0.02 (-0.29%)

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 07

    Mar

  • 18

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 30

    May

BAC Bank of America
$32.42

0.39 (1.22%)

01/31/18
DBAB
01/31/18
NO CHANGE
Target $15
DBAB
Sell
GE likely to be dropped from Dow 30 index, says Deutsche Bank
General Electric (GE) is likely to be dropped from the Dow Jones Industrial Average after being in the index of 30 companies for over 110 years as an original member since 1896, Deutsche Bank analyst John Inch tells investors in a research note. The chances that GE could be removed from the Dow are increasing as the company continues to face "substantial challenges," the analyst writes. These include "earnings and cash pressure, tough global power generation markets, aggressive downsizing, shrinking its portfolio, management shake-up and SEC investigations," Inch argues. He sees "headline risk" as the most significant risk factor if GE were to be dropped from the Dow, "potentially amplified by GE's high mix of retail investors." Inch notes that the last major Dow shakeup occurred in September 2003, when American Airlines (AAL), Bank of America (BAC) and Hewlett Packard (HPQ) were removed and Goldman Sachs (GS), Nike (NKE) and Verizon (VZ) were added. Inch has a Sell rating on General Electric with a $15 price target. The shares closed yesterday down 33c to $15.95.
01/18/18
RBCM
01/18/18
NO CHANGE
Target $35
RBCM
Outperform
Bank of America price target raised to $35 from $30 at RBC Capital
RBC Capital analyst Gerard Cassidy raised his price target on Bank of America to $35, citing a "strong all around performance" in Q4 along with the bank's commitment to keeping a low expense and growing top line profile. Cassidy says the bank remains "rate sensitive" and expects some $3.3B in net interest income from a 100bps move in short term rates. The analyst also keeps his Outperform rating on Bank of America, pointing to a positive impact from a stronger U.S. economy on its businesses, along with the return of excess capital, supporting a higher stock price view.
01/18/18
BMOC
01/18/18
NO CHANGE
Target $34
BMOC
Market Perform
Bank of America price target raised to $34 from $31 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Bank of America to $34 despite its "expense-driven" miss on Q4 earnings. Fotheringham says he remains bullish on banks based on the "indirect benefits of tax reform", while keeping his Market Perform rating on Bank of America given its two-year forward PE valuation trading around long-term historical average.
02/02/18
MSCO
02/02/18
NO CHANGE
MSCO
BofA, JPMorgan, Citi best positioned for tougher CCAR test, says Morgan Stanley
Morgan Stanley analyst Betsy Graseck said she had expected an easier stress test from the Federal Reserve but that the 2018 CCAR test actually seems tougher than last year, given the more intense recessions and lower asset prices modeled in it. A tougher test makes her less optimistic on her strong payout growth expectations, said Graseck, who sees Bank of America (BAC), JPMorgan (JPM) and Citi (C) as best positioned to "weather the storm" and increase payouts given their resilient balance sheets and significant excess capital. She sees Goldman Sachs (GS), which recently cut buybacks, as at risk from a tougher test, which likely weighs on the bank's 2018 ask, Graseck added.
MU Micron
$47.98

1.45 (3.12%)

02/20/18
JPMS
02/20/18
NO CHANGE
Target $60
JPMS
Overweight
JPMorgan sees continued outperformance for shares of Micron
JPMorgan analyst Harlan Sur expects shares of Micron Technology to continue outperforming following his firm's sixth consecutive positive revision to its near/mid-term "Global Memory Model." The analyst raised his estimates for Micron and expects supply of DRAM to remain tight/balanced through 2018. While average selling prices should return to typical sequential declines later in the year, Micron will likely drive margins higher in 2018 on continued cost reductions in NAND and DRAM, Sur tells investors in a research note. The analyst maintains an Overweight rating on the shares with a $60 price target.
02/06/18
02/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Barclays analyst Paul Cheng upgraded Chevron (CVX) to Overweight from Equal Weight and raised his price target for the shares to $135 from $130. The analyst recommends investors shift to Chevron from Exxon Mobil (XOM), a stock he double downgraded this morning to Underweight. Chevron's fundamentals are improving at a faster pace than many of the other mega majors, Cheng said. 2. Micron (MU) upgraded to Overweight from Sector Weight at KeyBanc by analyst Weston Twigg. Following the company's positive preannouncement amid "strong" DRAM pricing, the valuation and long-term trends "are too compelling to ignore," Twigg said. Micron was also upgraded to Strong Buy from Buy at Needham. 3. Skyworks (SWKS) upgraded to Outperform from Market Perform at BMO Capital by analyst Ambrish Srivastava, who cited the company's "ability to sustain a higher level of free cash flows to sales ratio than in the past and its commitment to higher capital allocation." Skyworks was also upgraded to Buy from Hold at Summit Insights. 4. HSBC (HSBC) upgraded to Hold from Sell at Santander. 5. RBS (RBS) upgraded to Neutral from Underperform at BofA/Merrill by analyst Michael Helsby, who said the rise in rates has led to a steeper yield curve in the U.K. which should result in higher earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/21/18
COWN
02/21/18
NO CHANGE
Target $53
COWN
Outperform
Micron joint venture with Intel remains underappreciated, says Cowen
After conducting field work across the semi supply chain, Cowen analyst Karl Ackerman said he believes Micron's (MU) joint venture with Intel (INTC) remains underappreciated by investors. Ackerman reiterated his Outperform rating and $53 price target on Micron shares.
02/06/18
02/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Radware (RDWR) downgraded to In-Line from Outperform at Imperial Capital by analyst Michael Kim, who reduced his estimates to reflect elevated uncertainty in the timing and magnitude of purchase orders, particularly from Tier 1 carriers. He sees limited downside from current share levels, however. 2. Micron (MU) downgraded to Hold from Buy at Summit Insights. Micron was upgraded to Strong Buy at Needham and to Overweight from Sector Weight at KeyBanc. 3. Exxon Mobil (XOM) downgraded to Underweight from Overweight at Barclays by analyst Paul Cheng, who recommended investors shift from Exxon Mobil to Chevron (CVX), a stock he upgraded this morning to Overweight. Exxon may not be able to maintain its historical valuation premium, Cheng tells investors in a research note. He thinks the company's valuation still reflects "rich historical norms," while the upstream's underlying fundamentals "appear to have suffered a structural deterioration." 4. Cirrus Logic (CRUS) downgraded to Hold from Buy Needham. 5. Catalent (CTLT) downgraded to Equal Weight from Overweight at Stephens by analyst Drew Jones, who believes there to be some conservatism in its guidance. However, he sees the potential for outperformance as less significant than in the past. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
XOM Exxon Mobil
$78.84

1.31 (1.69%)

01/19/18
COWN
01/19/18
NO CHANGE
Target $100
COWN
Outperform
Exxon Mobil reserve replenishment uptrend important, says Cowen
Cowen analyst Sam Margolin noted the positive turn in Exxon's reserve replacement trend for the first time since year-end 2014. The analyst said although it is not a goal of the company, it is important to the market and he said this single data point could initiate a longer stretch of relative share price performance. Margolin reiterated his Outperform rating and $100 price target on Exxon shares.
02/06/18
LEHM
02/06/18
UPGRADE
Target $135
LEHM
Overweight
Chevron upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Paul Cheng upgraded Chevron to Overweight and raised his price target for the shares to $135 from $130. The analyst recommends investors shift to Chevron from Exxon Mobil (XOM), a stock he double downgraded this morning to Underweight. Chevron's fundamentals are improving at a faster pace than many of the other mega majors, Cheng tells investors in a research note. He views the stock's risk/reward as attractive.
02/06/18
LEHM
02/06/18
DOWNGRADE
Target $84
LEHM
Underweight
Exxon Mobil downgraded to Underweight from Overweight at Barclays
Barclays analyst Paul Cheng double downgraded Exxon Mobil (XOM) to Underweight from Overweight and lowered his price target for the shares to $84 from $91. The analyst recommends investors shift from Exxon Mobil to Chevron (CVX), a stock he upgraded this morning to Overweight. Exxon closed yesterday down $4.81 to $79.72. Exxon may not be able to maintain its historical valuation premium, Cheng tells investors in a research note. He thinks the company's valuation still reflects "rich historical norms," while the upstream's underlying fundamentals "appear to have suffered a structural deterioration." Exxon's upstream problem "may take years or even a decade to overcome," Cheng argues.
CELG Celgene
$96.49

0.88 (0.92%)

01/29/18
WELS
01/29/18
NO CHANGE
Target $23
WELS
Outperform
Iovance Biotherapeutics price target raised to $23 from $17.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics (IOVA) to $23 following feedback from a "prominent cell therapy expert" late last week. The expert described expanding capacity for Gilead's (GILD) Yescarta, skepticism on Celgene (CELG) and Juno Therapeutics' (JUNO) claims around broad outpatient CAR-T opportunity for JCAR17, and a preference for tumor infiltrating lymphocyte therapeutics from Iovance for solid tumors over T-Cell receptor therapeutics being developed by a large number of companies, Birchenough tells investors in a research note. He reiterates Outperform ratings on both Iovance and Gilead.
02/09/18
PIPR
02/09/18
NO CHANGE
PIPR
Piper Jaffray reiterates Outperform on Crispr after CSO departure
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $39 price target on Crispr Therapeutics, despite Crispr trading down over 13% on news that Dr. Bill Lundberg is stepping down as Chief Scientific Officer and Celgene (CELG) has reduced its stake in the company to 6.1% from 8.0%. Tenthoff said he remains focused on Crispr's "therapeutic opportunity with first-in-man CTX001 Beta thalassemia and potentially sickle cell disease data this year."
02/13/18
02/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JPMorgan (JPM) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying he views the recent pullback in the shares as a buying opportunity. 2. Total (TOT) upgraded to Overweight from Equal Weight at Morgan Stanley and to Strong Buy from Outperform at Raymond James. 3. Celgene (CELG) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying the current valuation largely reflects the risk. 4. Quest Diagnostics (DGX) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. 5. Boeing (BA) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/18
LEHM
02/13/18
UPGRADE
Target $105
LEHM
Overweight
Celgene upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Celgene to Overweight with an unchanged price target of $105. The analyst remains concerned about Revlimid concentration risk long-term, but says the current valuation largely reflects the risk. Since the highs in October 2017, the stock has dropped $55 per share, Meacham tells investors in a research note. He notes Celgene's risk/reward profile based on his net present value analysis yields an "attractive upside case."
M Macy's
$27.45

0.71 (2.66%)

01/05/18
BMOC
01/05/18
NO CHANGE
Target $38
BMOC
Outperform
Macy's price target raised to $38 from $35 at BMO Capital
BMO Capital analyst Wayne Hood raised his price target on Macy's to $38 and kept his Outperform rating after the company's Nov-Dec comps completed the first positive SSS Q4 since 2014. Hood notes "encouraging" improvement in brick-and-mortar comps as well as double digit growth in digital platforms, forecasting further upside from " improving consumer spending setup from tax reform and falling unemployment that could be far reaching". The analyst raises his FY17 EPS forecast to $3.63 from $3.53 and FY18 forecast to $3.18 from $2.63, reflecting a lower effective tax rate of about 25%.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $100
JEFF
Buy
Bon-Ton Stores bankruptcy benefits Kohl's, says Jefferies
Jefferies analyst Randal Konik notes that Bon-Ton Stores filed bankruptcy protection and provided the locations of the about 50 units slated for closure. The analyst now estimates near-term closures from Macy's (M), Sears (SHLD), Kmart, and Bon-Ton (BONT) should add about 18c to Kohl's (KSS) EPS and a 1.5% comp lift. Moreover, Konik believes the materialization of Bon-Ton's closures could be a "cherry on top" to accelerating fundamentals at Kohl's this year. He reiterates a Buy rating and $100 price target on Kohl's shares.
01/02/18
MSCO
01/02/18
NO CHANGE
MSCO
Kohl's, Macy's Q4 same-store sales estimates raised at Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said that overall retail traffic appeared solid following Christmas, adding that store checks and third party data points suggest better performance at Kohl's (KSS) and Macy's (M) than she originally anticipated. Greenberger raised her Q4 Kohl's comparable sales estimate to down 1% from down 3% and increased her comp sales estimate for Macy's to down 2% from down 2.5%. However, she maintains an Underweight rating on Kohl's shares and an Equal Weight rating on Macy's.
12/18/17
OTRG
12/18/17
UPGRADE
OTRG
Mixed
Macy's upgraded to Mixed from Negative at OTR Global
OTR Global upgraded Macy's to Mixed following checks that indicate sell-through is meeting or exceeding plan driven by strong ecommerce trends.
RIG Transocean
$9.67

-0.03 (-0.31%)

10/19/17
HSBC
10/19/17
INITIATION
Target $11.5
HSBC
Hold
Transocean initiated with a Hold at HSBC
HSBC analyst David Phillips started Transocean with a Hold rating and $11.50 price target. The analyst sees a lack of potential upside given the company's "weaker medium-term liquidity profile."
01/04/18
JEFF
01/04/18
UPGRADE
Target $13
JEFF
Buy
Transocean upgraded to Buy from Hold at Jefferies
Jefferies analyst Brad Handler upgraded Transocean to Buy with an increased price target of $13. The analyst believes the company has earnings stability relative to peers and finds the valuation "cheap" at current levels.
01/23/18
LEHM
01/23/18
DOWNGRADE
Target $10
LEHM
Underweight
Rowan Companies downgraded to Underweight from Equal Weight at Barclays
Barclays analyst J. David Anderson downgraded Rowan Companies (RDC) to Underweight and lowered his price target for the shares to $10 from $14. The analyst views the offshore drillers as "highly overvalued" following the recent share rallies. He cut his near-term floater forecast to $150,000 per day from $235,000 per day and now sees 35% average downside to offshore drillers. Anderson this morning also downgraded Diamond Offshore (DO) to Underweight and cut his price target on Ensco (ESV) to $4 from $6, on Noble Corp. (NE) to $4 from $5 and on Transocean (RIG) to $7 from $9.
10/12/17
10/12/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Delta Air Lines (DAL) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying the company is likely to grow unit revenues in fiscal year 2018 due to pricing power in its key domestic hubs and improving international results. 2. Transocean (RIG) upgraded to Buy from Neutral at Citi with analyst Scott Gruber saying if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. 3. Canadian Pacific (CP) upgraded to Overweight from Neutral at JPMorgan with analyst Brian Ossenbeck saying he sees a shift to stronger volume growth as the company laps contract losses and records some new contract wins. 4. Infinity upgraded to Outperform from Market Perform at Wells Fargo with analyst Jim Birchenough saying the IPI-549 monotherapy data have a "reasonable likelihood" of proof-of-concept response rate, and with likely validation of tumor macrophage targeting in immunooncology and a unique mechanism of action, upside potential is not reflected in the current stock price. 5. Kroger (KR) upgraded to Equal Weight from Underweight at Stephens with analyst Ben Bienvenu saying he believes the pursuit of strategic alternatives for the convenience store business has potential to unlock value and that the risk/reward is more balanced following the stock's recent pullback. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MDLZ Mondelez
$44.77

1.02 (2.33%)

01/29/18
RBCM
01/29/18
NO CHANGE
RBCM
RBC estimates Mondelez stake in Keurig worth $3B after deal
As part of Keurig Green Mountain and Dr Pepper Snapple's (DPS) merger agreement, JAB will make an equity investment of $9B to finance the deal. Mondelez's (MDLZ) stake in Keurig will be reduced from 24.24% to 13%-14%. RBC Capital analyst David Palmer estimates the value of Mondelez's stake at around $3B. Based on the current Dr Pepper Snapple share price, Palmer thinks Mondelez's stake is up 50% since March 2016. He continues to see upside to Mondelez's stakes in both Jacobs Douwe Egberts and Keurig. The analyst keeps an Outperform rating on Mondelez shares. The stock in midday trading is down 5c to $44.37.
02/02/18
02/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. MasterCard (MA) upgraded to Buy from Hold at Argus with analyst Stephen Biggar saying the stock should trade above its historical average earnings multiple, with effective tax rate of 20% seen below 27% in 2017 as well as continued strong purchase volumes and growth in cross-border volumes and processed transactions. 2. Tableau (DATA) upgraded to Hold from Sell at Maxim with analyst Nehal Chokshi citing normalized bookings accelerating to 26% growth in the fourth quarter and sees normalized sales productivity stabilizing at about a 33% level. 3. Mondelez (MDLZ) upgraded to Buy from Hold at Societe Generale with analyst Warren Ackerman saying fourth quarter results were "solid" as emerging markets are rebounding strongly and the worst is over in North America. 4. Huntington Ingalls (HII) upgraded to Outperform from Market Perform at Cowen with analyst Gautam Khanna saying the shares are "excessively discounted" relative to the large cap defense peer average. 5. Sherwin-Williams (SHW) upgraded to Buy from Neutral at Seaport Global with analyst Michael Harrison saying the Valspar deal adds another layer of potential growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/18
SOCG
02/02/18
UPGRADE
Target $55
SOCG
Buy
Mondelez upgraded to Buy following 'solid' Q4 at Societe Generale
As previously reported, Societe Generale upgraded Mondelez to Buy from Hold with a $55 price target, up from $45. Analyst Warren Ackerman said Q4 results were "solid" as emerging markets are rebounding strongly and the worst is over in North America. Ackerman things 2018 guidance is conservative and the strategic review could unlock further potential upside.
02/02/18
SOCG
02/02/18
UPGRADE
SOCG
Buy
Mondelez upgraded to Buy from Hold at Societe Generale
CL Colgate-Palmolive
$71.07

0.77 (1.10%)

01/29/18
MSCO
01/29/18
NO CHANGE
Target $82
MSCO
Overweight
Colgate-Palmolive guidance 'clearly' seems conservative, says Morgan Stanley
Morgan Stanley analyst Dara Mohsenian said Colgate-Palmolive's 2018 EPS guidance clearly looks conservative and he sees positive revisions as likely, assuming consensus moves closer to the company's view. Despite Colgate's weaker than expected organic sales rebound in Q4, he still views the stock as a relative outperformer in 2018 as he expects organic sales growth towards the high-end of consumer packaged goods peers and he is forecasting ad spending will be up 12.5% year-over-year, Mohsenian tells investors. He trimmed his price target on Colgate shares to $82 from $83 and keeps an Overweight rating.
12/19/17
12/19/17
UPGRADE
Target $81

Outperform
Colgate-Palmolive upgraded to Outperform, business turning, says Macquarie
As previously reported, Macquarie upgraded Colgate-Palmolive to Outperform from Neutral and raised its price target to $81 from $71. Analyst Caroline Levy said the US business continues to improve with resin pricing expected to ease in 2H18. Measured channel sales were up 1.9% in the 4 weeks ended November 19, following ten negative months, and Palmolive dish detergent was up 1.8% after a year of declines, the analyst wrote in a note to investors. Levy thinks organic sales growth will re-accelerate in Q4 to +2.5%, and to +4% in 1H18 and earnings growth of +7%-8% in 2018-19 on improved growth prospects in the US and Europe, currency, and recent M&A.
12/27/17
JEFF
12/27/17
NO CHANGE
JEFF
Nielsen shows improved two-week sales trends, says Jefferies
Jefferies analyst Kevin Grundy says two-week sales growth in U.S. Nielsen channels improved sequentially for key home and personal care companies Colgate-Palmolive (CL), Church & Dwight (CHD) and Clorox (CLX), as well as beverage companies Monster Beverage (MNST), Coca-Cola (KO) and Dr Pepper Snapple (DPS). While overall growth remains tepid, sequential improvement in December for consumer spending, including staples, has been more upbeat, Grundy tells investors in a research note titled "Party Like It's 1999? Not Quite, But US Nielsen HPC/Bevs 2-Week Data Improves." The analyst favors shares of Church & Dwight, Procter & Gamble (PG), Dr Pepper and Monster.
01/30/18
EXAN
01/30/18
DOWNGRADE
EXAN
Underperform
Colgate-Palmolive downgraded to Underperform at Exane BNP Paribas
W Wayfair
$75.01

-0.24 (-0.32%)

02/23/18
PIPR
02/23/18
NO CHANGE
Target $112
PIPR
Overweight
Piper reiterates Overweight on Wayfair with $112 price target
Wayfair's Q4 results and conference call yesterday had elements that should please both bulls and bears alike, Piper Jaffray analyst Peter Keith tells investors in a post-earnings research note. To the positive, sales growth for both Q4 and Q1 is running well ahead of expectations and doesn't suggest competitive impact from Amazon (AMZN) and others, Keith contends. To the negative, the analyst points out, is Q4 EBITDA results and primarily the Q1 EBITDA guidance "further kick the can down the road on future profitability." The analyst views the outlook as disappointing, but believes Wayfair appears to be investing from a position of strength. Keith reiterates an Overweight rating on the shares with a $112 price target. He believes the stock, after yesterday's selloff, is now "back to a very reasonable" one times his 2018 sales estimate.
02/23/18
DADA
02/23/18
NO CHANGE
Target $65
DADA
Neutral
Wayfair price target lowered to $65 from $86 at DA Davidson
DA Davidson analyst Tom Forte lowered his price target on Wayfair to $65, updating his model based on the company's decision to accelerate investment spending his year. Forte keeps his Neutral rating on the stock, noting that the current price reflects his favorable view of the company's long-term prospects and that there is nothing wrong with Wayfair's business conditions or the managements strategy of investing for growth.
02/23/18
MKMP
02/23/18
NO CHANGE
Target $91
MKMP
Buy
Wayfair price target lowered to $91 from $107 at MKM Partners
MKM Partners analyst Patrick McKeever lowered his price target on Wayfair to $91 after a Q4 earnings miss, stating that while revenues accelerated, customer growth has slowed and Q1 earnings will be further constrained by rising investment spending. McKeever keeps his Buy rating on Wayfair longer term, adding that an aggressive spend in advertising and personnel should drive even stronger top-line growth than previously expected.
02/23/18
ADAM
02/23/18
NO CHANGE
Target $90
ADAM
Buy
Wayfair weakness a buying opportunity, says Canaccord
Canaccord analyst Michael Graham said Wayfair reported solid Q4 results and called the pace of its growth "impressive." The analyst believes the stock will continue to be volatile as the company continues to reinvest for growth, putting pressure on margins. Graham said the volatility will create entry points for long-term investors and reiterated his Buy rating and $90 price target on Wayfair shares.
ENDP Endo
$6.84

-0.02 (-0.29%)

02/14/18
02/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hershey (HSY) reinstated with a Neutral at JPMorgan. 2. Customers Bancorp (CUBI) initiated with a Neutral at DA Davidson. 3. Restoration Robotics (HAIR) initiated with a Buy at Craig-Hallum. 4. Nuvectra (NVTR) initiated with an Outperform at JMP Securities. 5. Endo (ENDP) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/18
JMPS
02/26/18
DOWNGRADE
JMPS
Market Perform
Endo downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Donald Ellis downgraded Endo to Market Perform from Outperform, stating that the company has a consistently declining branded base business and base generics business and he believes it has been very difficult for Endo to deleverage its balance sheet. Ellis downgraded the stock to Market Perform as his final rating, as JMP is terminating coverage of Endo International to reallocate research resources.
02/23/18
LEHM
02/23/18
NO CHANGE
Target $10
LEHM
Equal Weight
Endo price target lowered to $10 from $15 at Barclays
Barclays analyst Douglas Tsao lowered his price target for Endo International to $10 saying he remains cautious on the shares into the Q4 earnings report. The analyst keeps an Equal Weight rating on the name.
02/26/18
LEER
02/26/18
NO CHANGE
LEER
Outperform
Potential settlement on Testosterone step in right direction for Endo, says Leerink
Leerink analyst Ami Fadia notes that in the Multidistrict Litigation 2545 regarding Testosterone Replacement Therapy Products Liability Litigation, the parties involved including Endo entered into a Memorandum of Understanding on a potential global settlement. While the analyst acknowledges that investors remain cautious on the ultimate financial impact of the mesh liabilities, she believes this is another step in the right direction that Endo is taking to put the overhang from litigation proceedings behind it. Fadia thinks that as management moves to settle pending litigation, this will shift focus back to the operational aspects of the company, which are "underappreciated."

TODAY'S FREE FLY STORIES

TWTR

Twitter

$44.49

-0.775 (-1.71%)

12:44
07/15/18
07/15
12:44
07/15/18
12:44
Periodicals
Twitter suspends accounts linked to Russians indicted by Mueller, Reuters says »

Twitter has suspended two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 27

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:29
07/15/18
07/15
12:29
07/15/18
12:29
Periodicals
Trump says he will run for reelection, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

12:22
07/15/18
07/15
12:22
07/15/18
12:22
Periodicals
Airbus in talks for repeat Viva Aerobus jet order, Reuters says »

Airbus is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$350.81

4.79 (1.38%)

12:19
07/15/18
07/15
12:19
07/15/18
12:19
Periodicals
Boeing concerned about tariff talk, Reuters reports »

Boeing is concerned about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:17
07/15/18
07/15
12:17
07/15/18
12:17
Periodicals
President Trump calls EU a 'foe' on trade, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$203.32

1.29 (0.64%)

12:14
07/15/18
07/15
12:14
07/15/18
12:14
Hot Stocks
L3 Technologies appoints new SVP, Chief Global Business Development Officer »

L3 Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$207.33

0.43 (0.21%)

, TWTR

Twitter

$44.49

-0.775 (-1.71%)

13:27
07/14/18
07/14
13:27
07/14/18
13:27
Periodicals
Facebook, Alphabet to testify at U.S. House hearing, Reuters reports »

The U.S. House Judiciary…

FB

Facebook

$207.33

0.43 (0.21%)

TWTR

Twitter

$44.49

-0.775 (-1.71%)

GOOG

Alphabet

$1,188.81

4.94 (0.42%)

GOOGL

Alphabet Class A

$1,204.34

2.43 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 27

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

AAPL

Apple

$191.32

0.19 (0.10%)

, T

AT&T

$31.66

-0.56 (-1.74%)

13:06
07/14/18
07/14
13:06
07/14/18
13:06
Periodicals
Apple's next iPhone may be debut of eSIM, Barron's says »

Apple's (AAPL) next…

AAPL

Apple

$191.32

0.19 (0.10%)

T

AT&T

$31.66

-0.56 (-1.74%)

VZ

Verizon

$51.41

0.17 (0.33%)

S

Sprint

$5.66

(0.00%)

TMUS

T-Mobile

$61.68

0.09 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Aug

AEP

American Electric

$70.37

-0.02 (-0.03%)

, NEE

NextEra Energy

$169.60

1.06 (0.63%)

12:57
07/14/18
07/14
12:57
07/14/18
12:57
Periodicals
Utility stocks worth a second look, Barron's says »

Utility stocks like…

AEP

American Electric

$70.37

-0.02 (-0.03%)

NEE

NextEra Energy

$169.60

1.06 (0.63%)

XEL

Xcel Energy

$46.26

-0.09 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

, CA

CA Technologies

$44.07

-0.08 (-0.18%)

12:50
07/14/18
07/14
12:50
07/14/18
12:50
Periodicals
Broadcom testing investors' faith, Barron's says »

For a while, shareholders…

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

CA

CA Technologies

$44.07

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$23.40

-0.84 (-3.47%)

, HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

12:16
07/14/18
07/14
12:16
07/14/18
12:16
Periodicals
Ackman might be making a comeback, Barron's says »

Bill Ackman's…

VRX

Valeant

$23.40

-0.84 (-3.47%)

HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 27

    Aug

ARNC

Arconic

$17.39

0.08 (0.46%)

, APO

Apollo Global

$36.13

0.26 (0.72%)

08:41
07/14/18
07/14
08:41
07/14/18
08:41
Periodicals
Apollo, other PE firms express interest in Arconic, WSJ reports »

Arconic (ARNC) has…

ARNC

Arconic

$17.39

0.08 (0.46%)

APO

Apollo Global

$36.13

0.26 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

PFE

Pfizer

$37.53

0.01 (0.03%)

, BABA

Alibaba

$190.03

-0.14 (-0.07%)

08:23
07/14/18
07/14
08:23
07/14/18
08:23
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

PFE

Pfizer

$37.53

0.01 (0.03%)

BABA

Alibaba

$190.03

-0.14 (-0.07%)

BIDU

Baidu

$267.20

-4.31 (-1.59%)

JD

JD.com

$38.27

-0.25 (-0.65%)

IQ

iQIYI

$33.92

-1.12 (-3.20%)

VIPS

Vipshop

$10.23

-0.09 (-0.87%)

NYT

New York Times

$25.60

-0.6 (-2.29%)

PLNT

Planet Fitness

$48.71

1.2 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

  • 10

    Sep

XYL

Xylem

$68.55

0.485 (0.71%)

, AQUA

Evoqua Water

$20.71

(0.00%)

04:55
07/14/18
07/14
04:55
07/14/18
04:55
Conference/Events
RBC Capital to hold a field trip »

Asia Water Sector Field…

XYL

Xylem

$68.55

0.485 (0.71%)

AQUA

Evoqua Water

$20.71

(0.00%)

DHR

Danaher

$99.25

-0.4 (-0.40%)

PNR

Pentair

$43.53

0.67 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 07

    Aug

HJLI

Hancock Jaffe Laboratories

$3.20

-0.025 (-0.78%)

18:20
07/13/18
07/13
18:20
07/13/18
18:20
Hot Stocks
Hancock Jaffe Laboratories names Bob Rankin as CFO, effective July 16 »

Hancock Jaffe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CKH

Seacor

$53.63

0.69 (1.30%)

, LPG

Dorian LPG

$7.92

0.115 (1.47%)

18:16
07/13/18
07/13
18:16
07/13/18
18:16
Hot Stocks
Seacor favors combination of Dorian LPG and BW LPG Limited »

Seacor (CKH) announced…

CKH

Seacor

$53.63

0.69 (1.30%)

LPG

Dorian LPG

$7.92

0.115 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:53
07/13/18
07/13
17:53
07/13/18
17:53
Hot Stocks
Senator Rubio says ZTE 'should be put out of business' »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TEVA

Teva

$23.29

-0.45 (-1.90%)

, NVS

Novartis

$78.78

-0.15 (-0.19%)

17:47
07/13/18
07/13
17:47
07/13/18
17:47
Hot Stocks
FDA announces voluntary recall of several medicines containing valsartan »

The U.S. Food and Drug…

TEVA

Teva

$23.29

-0.45 (-1.90%)

NVS

Novartis

$78.78

-0.15 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:26
07/13/18
07/13
17:26
07/13/18
17:26
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:25
07/13/18
07/13
17:25
07/13/18
17:25
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIO

Mustang Bio

$7.49

0.09 (1.22%)

17:24
07/13/18
07/13
17:24
07/13/18
17:24
Syndicate
Breaking Syndicate news story on Mustang Bio »

Mustang Bio files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

, XLU

Utilities SPDR

$52.56

0.04 (0.08%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
General news
Week ending ETF Scorecard: Industrials rebound into lead, Utilities lag »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

XLU

Utilities SPDR

$52.56

0.04 (0.08%)

IYR

DJ US Real Estate Index Fund

$81.37

-0.19 (-0.23%)

XLP

Consumer Staples Sector SPDR

$52.73

0.32 (0.61%)

XLY

Consumer Discretionary Sector SPDR

$112.62

0.27 (0.24%)

XLB

S&P Select Materials SPDR

$58.59

-0.02 (-0.03%)

XLF

Financial Select Sector

$26.96

-0.13 (-0.48%)

XLV

Health Care Select Sector SPDR

$87.44

0.18 (0.21%)

XLK

Technology Select Sector SPDR

$72.56

-0.07 (-0.10%)

XLI

Industrial Select Sector SPDR

$73.77

0.43 (0.59%)

GLD

SPDR Gold Trust

$117.60

-0.515 (-0.44%)

SLV

iShares Silver Trust

$14.88

-0.13 (-0.87%)

USO

United States Oil Fund

$14.47

0.085 (0.59%)

UNG

United States Natural Gas Fund

$22.40

-0.3 (-1.32%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.63

0.005 (0.01%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.76

0.16 (0.14%)

TLT

iShares 20+ Year Treasury Bond Fund

$122.74

0.33 (0.27%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.60

0.165 (0.16%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

0.025 (0.03%)

IWD

iShares Russell 1000 Value

$123.04

-0.07 (-0.06%)

IWF

iShares Russell 1000 Growth

$149.33

0.33 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$1.04

-0.015 (-1.42%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
Hot Stocks
CEL-SCI receives noncompliance letter from NYSE »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$53.47

-0.18 (-0.34%)

17:13
07/13/18
07/13
17:13
07/13/18
17:13
Hot Stocks
Yankees suspend relationship with Papa John's »

The New York Yankees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NCNA

NuCana

$24.00

-0.01 (-0.04%)

17:08
07/13/18
07/13
17:08
07/13/18
17:08
Hot Stocks
Breaking Hot Stocks news story on NuCana »

Christopher B. Wood…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.